Clinical Significance of Venous Thromboembolism in Patients with Advanced Cholangiocarcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Patients with active cancer frequently develop venous thromboembolism (VTE). However, there is little data about VTE in patients with advanced cholangiocarcinoma (CCA). Therefore, we investigated the clinical significance of VTE in patients with advanced CCA. Methods: We analyzed the data of a total of 332 unresectable CCA patients diagnosed between 2010 and 2020 in this retrospective study. We investigated the incidence and risk factors for VTE, and its effect on survival in patients with advanced CCA. Results: During a median follow-up of 11.6 months, 118 patients (35.5%) developed VTE. The cumulative incidence of VTE was 22.4% (95% confidence interval [CI], 0.18 to 0.27) at 3 months and 32.8% (95% CI, 0.27 to 0.38) at 12 months. Major vessel invasion was an independent risk factor for VTE (hazard ratio, 2.88; 95% CI, 1.92 to 4.31; p<0.001). Patients who developed VTE during follow-up had shorter overall survival than patients who did not (11.50 months vs 15.83 months, p=0.005). In multivariable analysis, VTE (hazard ratio, 1.58; 95% CI, 1.23 to 2.02; p<0.001) was associated with poor overall survival. Conclusions: Major vessel invasion is related to the occurrence of VTE in advanced CCA. The development of VTE significantly decreases the overall survival and is an important unfavorable prognostic factor for survival.
Abstract
Background/Aims: Patients with active cancer frequently develop venous thromboembolism (VTE). However, there is little data about VTE in patients with advanced cholangiocarcinoma (CCA). Therefore, we investigated the clinical significance of VTE in patients with advanced CCA. Methods: We analyzed the data of a total of 332 unresectable CCA patients diagnosed between 2010 and 2020 in this retrospective study. We investigated the incidence and risk factors for VTE, and its effect on survival in patients with advanced CCA. Results: During a median follow-up of 11.6 months, 118 patients (35.5%) developed VTE. The cumulative incidence of VTE was 22.4% (95% confidence interval [CI], 0.18 to 0.27) at 3 months and 32.8% (95% CI, 0.27 to 0.38) at 12 months. Major vessel invasion was an independent risk factor for VTE (hazard ratio, 2.88; 95% CI, 1.92 to 4.31; p<0.001). Patients who developed VTE during follow-up had shorter overall survival than patients who did not (11.50 months vs 15.83 months, p=0.005). In multivariable analysis, VTE (hazard ratio, 1.58; 95% CI, 1.23 to 2.02; p<0.001) was associated with poor overall survival. Conclusions: Major vessel invasion is related to the occurrence of VTE in advanced CCA. The development of VTE significantly decreases the overall survival and is an important unfavorable prognostic factor for survival.
참고문헌 (29)
- Blom JW, "Incidence of venous thrombosis in a large cohort of 66, 329 cancer patients : results of a record linkage study", J Thromb Haemost, 4, pp.529~535 (2006)
- Lyman GH, "American Society of Clinical Oncology guideline : recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer", J Clin Oncol, 25, pp.5490~5505 (2007)
- Levitan N, "Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy : risk analysis using Medicare claims data", Medicine(Baltimore), 78, pp.285~291 (1999)
- Sørensen HT, "Prognosis of cancers associated with venous thromboembolism", N Engl J Med, 343, pp.1846~1850 (2000)
- Chew HK, "Incidence of venous thromboembolism and its effect on survival among patients with common cancers", Arch Intern Med, 166, pp.458~464 (2006)
- Thodiyil PA, "Variation in relative risk of venous thromboembolism in different cancers", Thromb Haemost, 87, pp.1076~1077 (2002)
- Bergquist A, "Epidemiology of cholangiocarcinoma", Best Pract Res Clin Gastroenterol, 29, pp.221~232 (2015)
- Rizvi S, "Pathogenesis, diagnosis, and management of cholangiocarcinoma", Gastroenterology, 145, pp.1215~1229 (2013)
- Shin HR, "Descriptive epidemiology of cholangiocarcinoma and clonorchiasis in Korea", J Korean Med Sci, 25, pp.1011~1016 (2010)
- Khan SA, "Guidelines for the diagnosis and treatment of cholangiocarcinoma : consensus document", Gut, 51(Suppl 6), pp.VI1~VI9 (2002)
- Jung K, "Realworld outcomes of gemcitabine, cisplatin, and nab-paclitaxel chemotherapy regimen for advanced biliary tract cancer : a propensity score-matched analysis", Gut Liver, 16, pp.798~805 (2022)
- Saha SK, "Forty-year trends in cholangiocarcinoma incidence in the U. S. : intrahepatic disease on the rise", Oncologist, 21, pp.594~599 (2016)
- Chung T, "Genetic, clinicopathological, and radiological features of intrahepatic cholangiocarcinoma with ductal plate malformation pattern", Gut Liver, 16, pp.613~624 (2022)
- Lu CD, "Outcomes of intrahepatic cholangiocarcinoma with portal vein tumor thrombus following hepatic resection", J Gastroenterol Hepatol, 31, pp.1330~1335 (2016)
- Uchida T, "Prediction of portal vein thrombosis following hepatectomy for perihilar cholangiocarcinoma : efficacy of postoperative portal vein diameter ratio and angle", Anticancer Res, 39, pp.5019~5026 (2019)
- Blasi A, "Prediction of thromboembolic complications after liver resection for cholangiocarcinoma : is there a place for thromboelastometry?", Blood Coagul Fibrinolysis, 29, pp.61~66 (2018)
- Lee KW, "The incidence, risk factors and prognostic implications of venous thromboembolism in patients with gastric cancer", J Thromb Haemost, 8, pp.540~547 (2010)
- Frere C, "Incidence of venous thromboembolism in patients with newly diagnosed pancreatic cancer and factors associated with outcomes", Gastroenterology, 158, pp.1346~1358 (2020)
- Valle JW, "Biliary cancer : ESMO clinical practice guidelines for diagnosis, treatment and follow-up", Ann Oncol, 27(suppl 5), pp.v28~v37 (2016)
- Lee DH, "Radiologic evaluation and structured reporting form for extrahepatic bile duct cancer : 2019 consensus recommendations from the Korean Society of Abdominal Radiology", Korean J Radiol, 22, pp.41~62 (2021)
- Khorana AA, "Development and validation of a predictive model for chemotherapy-associated thrombosis", Blood, 111, pp.4902~4907 (2008)
- Meira-Machado L, "Multi-state models for the analysis of time-toevent data", Stat Methods Med Res, 18, pp.195~222 (2009)
- Jeon HK, "Venous thromboembolism in patients with cholangiocarcinoma : focus on risk factors and impact on survival", Eur J Gastroenterol Hepatol, 24, pp.444~449 (2012)
- Mukai M, "Mechanism and management of cancerassociated thrombosis", J Cardiol, 72, pp.89~93 (2018)
- Khorana AA, "Venous thromboembolism and prognosis in cancer", Thromb Res, 125, pp.490~493 (2010)
- Han LY, "Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma", J Clin Oncol, 24, pp.755~761 (2006)
- Nitori N, "Prognostic significance of tissue factor in pancreatic ductal adenocarcinoma", Clin Cancer Res, 11, pp.2531~2539 (2005)
- Sano M, "Blocking VCAM-1 inhibits pancreatic tumour progression and cancer-associated thrombosis", thromboembolism, 2021, pp.70, 1713~1723
- Lyman GH, "Clinical practice guidelines for the treatment and prevention of cancer-associated thrombosis", Thromb Res, 191(Suppl 1), pp.S79~S84 (2020)